2,076 Shares in Zoetis Inc (ZTS) Acquired by CAPROCK Group Inc.

CAPROCK Group Inc. acquired a new position in Zoetis Inc (NYSE:ZTS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,076 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors have also modified their holdings of the stock. Whittier Trust Co. grew its stake in shares of Zoetis by 3.2% in the fourth quarter. Whittier Trust Co. now owns 4,039 shares of the company’s stock worth $345,000 after purchasing an additional 124 shares during the last quarter. North Star Investment Management Corp. lifted its holdings in Zoetis by 0.6% in the fourth quarter. North Star Investment Management Corp. now owns 22,525 shares of the company’s stock valued at $1,927,000 after buying an additional 125 shares during the period. Sandy Spring Bank lifted its holdings in Zoetis by 0.4% in the fourth quarter. Sandy Spring Bank now owns 29,716 shares of the company’s stock valued at $2,542,000 after buying an additional 125 shares during the period. InterOcean Capital LLC lifted its holdings in Zoetis by 5.0% in the fourth quarter. InterOcean Capital LLC now owns 2,945 shares of the company’s stock valued at $252,000 after buying an additional 139 shares during the period. Finally, CX Institutional lifted its holdings in Zoetis by 36.6% in the first quarter. CX Institutional now owns 694 shares of the company’s stock valued at $70,000 after buying an additional 186 shares during the period. 90.93% of the stock is currently owned by institutional investors.

In other news, CEO Juan Ramon Alaix sold 312,109 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $94.06, for a total transaction of $29,356,972.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Roxanne Lagano sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $101.89, for a total transaction of $203,780.00. Following the transaction, the insider now owns 30,727 shares in the company, valued at approximately $3,130,774.03. The disclosure for this sale can be found here. Insiders have sold 404,209 shares of company stock worth $38,052,349 in the last quarter. Company insiders own 0.35% of the company’s stock.



Several equities analysts recently issued reports on ZTS shares. UBS Group started coverage on shares of Zoetis in a report on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Sunday, January 6th. Credit Suisse Group boosted their target price on shares of Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a report on Tuesday, April 2nd. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and boosted their target price for the company from $97.00 to $110.00 in a report on Monday, March 4th. Finally, SunTrust Banks started coverage on shares of Zoetis in a report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $100.57.

Shares of NYSE ZTS opened at $101.26 on Tuesday. Zoetis Inc has a 1-year low of $77.00 and a 1-year high of $103.33. The stock has a market cap of $48.43 billion, a PE ratio of 32.35, a P/E/G ratio of 1.83 and a beta of 0.93. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 14th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the business earned $0.69 earnings per share. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc will post 3.46 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a dividend of $0.164 per share. The ex-dividend date is Wednesday, April 17th. This represents a $0.66 annualized dividend and a dividend yield of 0.65%. Zoetis’s dividend payout ratio is currently 21.09%.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://dakotafinancialnews.com/2019/04/16/2076-shares-in-zoetis-inc-zts-acquired-by-caprock-group-inc.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Why do companies issue stock splits?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.